The background frequency of t(14;18) (q32;q21) chromosomal tranlocations at the locus associated with B-cell leukemia/lymphoma-2 (BCL2) was determined from a survey ofthe peripheral blood lymphocytes (PBLs) of53 living Individuals and from tissues of 31 autopsies by using a nested PCR assay. The translocation was detected in 55% of It has been thought that most human tumor clones arise from a single transformed cell and that tumor progression is a multistep process requiring multiple mutational hits at oncogenes and tumor-suppressor genes (1-6). Since multiple hits at oncogenic loci are thought to be required for tumorigenesis, one might expect oncogenic mutations to occur in humans who have not yet developed tumors, given sufficiently sensitive techniques (7). The incidence of most tumors rises strikingly with age (8), and if mutational hits at oncogenic loci are a prerequisite for tumorigenesis, one might then expect the frequency of somatic mutations at oncogenic loci to rise with age. Although such expectations have existed for many years and evidence has accumulated that rare mutational hits accumulate at nononcogenic loci with age (9, 10), an age-related increase in mutations at an oncogenic locus has not been shown.
Translocations copurifled with B lymphocytes. The frequency of translocations significantly increased with age in PBLs and spleens, as does human risk for lymphoma. Average translocation frequency was more than 40 times greater in the spleen and 13 times greater in the peripheral blood in the oldest individuals (61 yr and older) compared with the youngest individuals (20 yr or younger). Particular t(14;18)-bearing clones persisted over a period of 5 months in two individuals. These findings demonstrate that clones harboring the oncogenic t(14;18) chromosomal translocation are commonly present in normal humans, that such clones are long-lived, and that they rise in frequency with age. A multihit model of lymphomagenesis involving t(14;18) translocation followed by antigen stimulation Is proposed.
It has been thought that most human tumor clones arise from a single transformed cell and that tumor progression is a multistep process requiring multiple mutational hits at oncogenes and tumor-suppressor genes (1) (2) (3) (4) (5) (6) . Since multiple hits at oncogenic loci are thought to be required for tumorigenesis, one might expect oncogenic mutations to occur in humans who have not yet developed tumors, given sufficiently sensitive techniques (7) . The incidence of most tumors rises strikingly with age (8) , and if mutational hits at oncogenic loci are a prerequisite for tumorigenesis, one might then expect the frequency of somatic mutations at oncogenic loci to rise with age. Although such expectations have existed for many years and evidence has accumulated that rare mutational hits accumulate at nononcogenic loci with age (9, 10) , an age-related increase in mutations at an oncogenic locus has not been shown.
Non-Hodgkin lymphoma (NHL) is a tumor of B-lymphocyte origin, whose incidence rises more than 40-fold with human age (11) . As in many other hematological neoplasms (12) (13) (14) , specific chromosomal translocations occur in the two types of NHL, follicular lymphoma and diffuse B-cell lymphoma (15) . The t(14;18)(q32;q21) translocation occurs in 85% of follicular lymphomas and 20% of diffuse B-cell lymphomas (11) . Such translocations juxtapose the BCL2 (B-cell leukemia/lymphoma-2) locus on chromosome 18 with the immunoglobulin heavy chain joining (J) region gene on chromosome 14, resulting in dysregulated expression of the BCL2 gene (16, 17) . Dysregulated expression of this locus prolongs the survival of B cells, by delaying programmed cell death (18, 19) .
We have developed a nested PCR assay for quantitation of rare t(14;18) translocations to test the hypotheses that such oncogenic mutations may occur (i) in persons without lymphoid neoplasia and (ii) in an age-dependent fashion.
MATERIALS AND METHODS
Preparation of DNA. Fifty-three blood samples from live persons and tissues from 31 autopsies were collected at the Los Angeles County Hospital, CA. Blood samples were kept at 40C no more than 72 hr prior to lymphocyte separation. PBLs were prepared as described by Boyum (20) and were frozen at -200C until DNA extraction. Autopsy tissues were maintained at -800C prior to DNA preparation and then minced with a razor blade, and DNA was extracted by standard methods (21) . All autopsy DNA samples were tested for degradation by a control PCR amplification with primers PA1 and Pc (5'-AAG GTC TGA TCA TTC TGTTCC) (Fig. 1) (Fig. 3) , supporting the notion that these signals were not the result of a single event of product contamination or in vitro PCR artifact but rather exhibited the size variation expected of breaks generated by the variable-diversity-J [V(D)J] recombinase in vivo. PCR products were then purified (Centricon 100) and directly sequenced (Fig. 4 ) by using 3.2 pmol of primer P2 (except for the sample from individual 29, for which P3 was used) and 0.5 pmol of double-stranded DNA template with a 373A automated DNA sequencer (Applied Biosystems). All nine determined sequences contained an identifiable fragment from the BCL2 locus, an N-segment, and one of the six J regions, characteristic of breaks mediated by the V(D)J recombinase (27) (Fig. 4) . The heterogeneity of the DNA sequence at thesejunctions supports the notion that the products amplified are t(14;18) translocations generated in vivo, rather than a PCR artifact generated in vitro. Samples from individuals 14 and 31 yielded multiple sequences. We infer that those spleens contain multiple clones of t(14;18)-bearing cells. Multiple bands were consistently amplified from the spleen ofindividual 14 (Fig. 3 , lane 4), supporting the notion that multiple independent t(14;18) events may occur in one individual.
Confirmation of Nested PCR Assay by PCR-Southern Assay for Translocations. We tested the agreement of the nested PCR t(14;18) assays with the previously described method (25, 26, 28) , which employs PCR amplification followed by Mg of DNA with outer primers PA, and P4 was performed for 30 cycles as described above, electrophoresed through 2.5% agarose, blotted to a nylon membrane, and probed with a fragment of the MBR prepared by primer extension of PA1 as described by Medori et al. (29) . The PCR-Southem method confirmed the nested PCR method for t(14;18) detection for all positives and all negatives in 20 representative samples (Fig. 5 ). In the experiment illustrated, samples from individuals 11 and 15 were negative by both nested PCR and PCR-Southern assay, consistent with the stochastic detection from these samples when 2 pg of DNA is used.
Estimation of Translocation Frequency. The concentration of the t(14;18) translocation in 2 pg of sample DNA was estimated by using a "multiple tubes approach" (7, 30) , and Poisson assumptions. Five replicates of 2 pg of PBL DNA (approximately 300,000 lymphocytes) and 10 replicates of 2 pg of autopsy tissue DNA were assayed. It was assumed that one or more t(14;18) molecules would be detected with an efficiency of nearly 100o%-a simplification that is justified based on our and other reconstruction experiments (7, (24) (25) (26) 31 errors of the V(D)J recombinase, an enzyme whose expression is limited to lymphoid cells. This lymphoid-specific distribution of mutation we report is consistent with reports by others that low levels of t(14;18) occur in human tonsils with hyperplastic lymphoid tissue (30, 32) . These data do not support the claim that V(D)J recombinase may be active in brain (33) . There is Extensive Quantitative Variation in BCL2 Translocation Frequency among Human Spleens and PBLs. Variation in BCL2 mutation frequency in spleens and PBLs was determined by the multiple tubes approach that is described in Materials and Methods. Thirty-one spleen samples were amplified in replicates of 10 trials. Of the 31 20 were never positive, 1 was positive in 4 trials, 2 were positive in 5 trials, 1 was positive in 6 trials, 3 were positive in 7 trials, and 4 were positive in 10 of 10 trials. Translocation frequency varied from 2 per million lymphocytes to 854 per million lymphocytes-a range of 420-fold (Table 1) .
For PBL samples, two ,ug of DNA of the 53 PBL samples were amplified in replicates of five trials each. In those five replicate amplifications, 24 samples of the 53 were never positive, 15 samples were positive once, 6 samples were positive twice, 3 samples were positive three times, 2 samples were positive four times, and 3 samples were positive 5 times. Translocation frequency varied from 0.8 per million lymphocytes to 32 per million lymphocytes-a range of 40-fold (Fig.  6) .
Frequency of the t(14;18) Translocation in PBLs and Spleens Is Significantly Correlated with Human Age. Given the known correlation between NHL incidence and human age, the correlation of t(14;18) frequency in PBLs versus age of donor was performed (Figs. 6 and 7) . The mean t(14;18) frequencies per million PBLs ± SEM in four age categories (category 1 = 0-20 yr; 2 = 21-40 yr; 3 = 41-60 yr; 4 = 61 yr and older) were, respectively, 0.29 + 0.13, 0.77 + 0.29, 1.43 ± 0.80, and 3.93 ± 1.58 (Fig. 7) .-There was a 13-fold increase on average in t(14;18) frequency between age category 1 and age category 4. The apparent increase in t(14;18) frequency was statistically significant by Spearman's rank correlation test of age versus translocation frequency (P = 0.0067, r, = 0. 37) and by a calculation of 95% confidence interval of t(14;18) frequency in the age categories 1 (0.29 ± 0.26) and 4 (3.93 ± 3.04).
A correlation of t(14;18) frequency in autopsied spleens with age was also performed. The calculated t(14;18) frequencies per million cells ± SEM were 0 ± 0, 2.1 ± 1.0, 24.7 + 21.6, and 146.3 + 144.2 in the four age categories (Fig. 7) . When we make the conservative estimate that there is one t(14;18) translocation or less per 2 Mg of DNA on average in the 10 spleens from age category 1, then there is a more than 40-fold increase in BCL2 mutation frequency on average between spleens of age categories 1 and 4. The correlation between translocation frequency and age of donor was statistically significant (Spearman's rank correlation test, P = 0.0005, rs = 0.59). The incidence of t(14;18) positives was also significantly higher among spleens 30 yr or older compared with spleens 29 yr or younger (P = 0.01, Fisher's Exact Test).
t(l4;18) Clones Persist in Human PBLs over a Period of 5 Months. Two individuals whose PBLs were positive for t(14;18) and three individuals who were negative were resurveyed for t(14;18) after several months. The two individuals positive for t (14;18) at to were reassayed at t1 (where t1 -to = 5 months) and were found to be positive again. The junction sequence amplified at to and t1 from the first individual was: TGGTATGAAGCCAG-GTCCGGAAGG-GAAAAAC-TACTACTACTACTAC, exhibiting sequence patterns of the BCL2 major breakpoint region, the N segment, and the use of J6. The amplified sequences from the second positive individual were TGAAATGCAGTGGTGC-AAACACAGTGCC-TACTACTACTACGGTATGG at to, and TGAAATGCAGTGGTGC-AAACACTGGGCC-TAC-TACTACTACGGTATGG at t1, identical except for one change in the N region between to and t, ( (8) .
Mutations in blood cells, including those caused by aberrant V(D)J recombinase activity, have been used as biomarkers of cancer risk (35, 36) , and many of these assays detect an increase in mutation frequency with age in blood cells (37, 38) . Aged people have at least a 40-fold higher risk for NHL, and we detected an increase of t(14;18) frequency in the aged (Fig. 7) . But the incidence of BCL2 mutations in spleens (35%) and PBLs (55%) is high compared with the lifetime risk for NHL (0.6%). One might rationalize these facts by postulating a multistep model of lymphomagenesis in which t(14;18)-bearing B cells reach numerical prominence by antigenic stimulation and subsequent malignancy by additional oncogenic mutations (Fig. 8) . These results appear homologous to the situation in transgenic mice that bear a dysregulated human BCL2 transgene in the germ line, in which development of follicular lymphoma is also rare (18, 39 
